Cargando…
ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer
BACKGROUND: One-third of estrogen (ER+) and/or progesterone receptor-positive (PGR+) breast tumors treated with Tamoxifen (TAM) do not respond to initial treatment, and the remaining 70% are at risk to relapse in the future. Estrogen-related receptor gamma (ESRRG, ERRγ) is an orphan nuclear receptor...
Autores principales: | Madhavan, Subha, Gusev, Yuriy, Singh, Salendra, Riggins, Rebecca B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436109/ https://www.ncbi.nlm.nih.gov/pubmed/25971350 http://dx.doi.org/10.1186/s13046-015-0150-9 |
Ejemplares similares
-
MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ*
por: Lü, Mingrong, et al.
Publicado: (2015) -
In Silico Discovery of Mitosis Regulation Networks Associated with Early Distant Metastases in Estrogen Receptor Positive Breast Cancers
por: Gusev, Yuriy, et al.
Publicado: (2013) -
ERRβ splice variants differentially regulate cell cycle
progression
por: Heckler, Mary Mazzotta, et al.
Publicado: (2014) -
Identification of Selective ERRγ Inverse Agonists
por: Kim, Jina, et al.
Publicado: (2016) -
Estrogen-related receptor β (ERRβ) – renaissance receptor or receptor renaissance?
por: Divekar, Shailaja D., et al.
Publicado: (2016)